Article
Dr. Jack Cush reviews the news and info reports the day before ACR 2025
All News
Article
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.
Article
Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.
Article
Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial lung disease (ILD) begins early in the course of RA, with certain factors enhancing this risk.
Md Yuzaiful Md Yusof
Tweet
#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any new biomarker which can link these ILD?
Measuring reactivity to MDA5 (aa 201-300) epitope peptide may help identify poor ILD prognostics (with/out DM) @RheumNow https://t.co/rziwihKfIr
Janet Pope
Tweet
What is the #frequency of #CTD #ILD in #USA?
Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts
56-65 yrs, 3/4 F
?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant
Same as Ont, Canada #SSc-ILD %
Not rare
#ACR25 @RheumNow @ACRheum
Abst#0154 https://t.co/imfSyOtYpC
Dr. John Cush
Tweet
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5
Akhil Sood MD, MS
Tweet
💊 SGLT2i vs GLP-1 in Lupus Nephritis
TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis
📊 GLP-1 use linked to better renal & CV outcomes in LN including:
⬇️ CKD progression
⬇️ Mortality
⬇️ Acute MI
@RheumNow #ACR25 https://t.co/v4LgKFDt68
David Liew
Tweet
Upadacitinib in GCA doesn't just affect IL-6, it alters IFNg, known to be important in vascular change in GCA.
If UPA in GCA has some cardiovascular concerns extrapolated from RA, it also has some plausible cardiovascular benefits too that TCZ may not
#ACR25 ABST0751 @RheumNow https://t.co/rMetLPP9z6
Aurelie Najm
Tweet
A closer look in skin toxicity of GCs in RMDs
GC Toxicity Index, LONG TOX prospective cohort
Frequent:
-Easy bruising 35%
-Atrophy 22%
-Hirsutism 17%
-Acneiform rash 15%
-Erosion/Tear 12%
GC-related Neuropsychiatric toxicity highly associated with/ skin, something to look out https://t.co/NfxG8JkxSP
sheila
Tweet
Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy
In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA
☝️Consider other dx if D2T PsA
#ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ
Jiha Lee
Tweet
ILD found in 30% of Sjögren’s pts w/ HRCT.
A new nomogram-based tool (AUC 0.8) predicts ILD risk using age, ESR, C3, hypergammaglobulinemia & anti-La/SSB.
Goal: guide HRCT referrals & catch ILD earlier.
@RheumNow #ACR25 Abstract #0510 https://t.co/FvAprq8eol
Akhil Sood MD, MS
Tweet
Statins and SLE: To add or not to add? 💊
Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses.
- No significant differences in MACE or ESKD.
@RheumNow #ACR25
sheila
Tweet
This retrospective cohort analysis by Dr. Lihi Eder et al showed that among patients with PsA, those w/ high dse activity & high 3VAS scores were assoc w/⬆️ risk of atrial tachyarrythmias.
Main message: PsA conveys ⬆️CV risk; inflamm control is key!
#ACR25 @RheumNow Abs0522 https://t.co/7sRM7K4V1c
Aurelie Najm
Tweet
A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies!
Japanese study
MDA5 (201-300) positivity associated w/
Lower 6-month progression-free survival (43% vs. 74%)
Lower 5-year survival rates (34% vs. 66%)
Validation in other populations awaited https://t.co/IBiYyATer4
Brian Jaros, MD
Tweet
How does cMRI change over time in cardiac EGPA?
Cheng et al. retrospectively reviewed:
- 11 EGPA pt with LGE on initial cMRI
Despite treatment:
- 10/11 persistent LGE on 2nd cMRI
- 4/4 on 3rd
- 2/2 on 4th
Unclear use as a monitor of tx response
@RheumNow #ACR25
Dr. John Cush
Tweet
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/O4Pi8GyT32
Dr. John Cush
Tweet
Single center study ANCA-assoc. vasculitis. From 78 pts had poor outcomes (16 ESKD, 15 deaths). Elevated BUN was a risk factor (adj HR 1.07). Risk factors for ESKD were baseline BUN & WBC. Risks for death included CV Dz (HR 8.7), NLR (1.04) &anti-PLt Rx (HR 6.8) https://t.co/QQrDmja0zo
Dr. John Cush
Tweet
SAIL-RA: Finding ILD in Early RA
Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial lung disease (ILD) begins early in the course of RA, with certain factors enhancing this risk.
https://t.co/nI0YuYd3YS https://t.co/YR3Gg1kr59
Dr. John Cush
Tweet
Retrospective study of 423 seropositiv RA pts (SPRA) finds 21% with baseline ILD; over 10 yrs 31% had ILD. High monocyte counts signif higher in RA-ILD; whereas RF, CCP did not predict. Age & ILD predicted mortality - not monocytes, RF or CCP https://t.co/8H4wqZI3WQ https://t.co/dK9iHwj3cz
